BioNTech SE (BNTX) Liabilities and Shareholders Equity (2018 - 2025)
BioNTech SE's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $25.6 billion for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 6.32% to $25.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $97.3 billion, a 0.53% increase, with the full-year FY2025 number at $24.8 billion, up 3.19% from a year prior.
- Liabilities and Shareholders Equity hit $25.6 billion in Q4 2025 for BioNTech SE, up from $24.9 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for BNTX hit a ceiling of $25.6 billion in Q4 2025 and a floor of $5.1 billion in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $21.7 billion across 5 years, with a median of $23.8 billion in 2022.
- Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 927.56% in 2021 and later fell 7.85% in 2025.
- Tracing BNTX's Liabilities and Shareholders Equity over 5 years: stood at $18.1 billion in 2021, then soared by 31.15% to $23.8 billion in 2022, then rose by 4.22% to $24.8 billion in 2023, then decreased by 2.74% to $24.1 billion in 2024, then rose by 6.32% to $25.6 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for BNTX at $25.6 billion in Q4 2025, $24.9 billion in Q3 2025, and $24.5 billion in Q2 2025.